oxidopamine has been researched along with Affective Disorders in 4 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
Excerpt | Relevance | Reference |
---|---|---|
"Parkinson's disease is a neurodegenerative disease characterized by progressive dopaminergic neuronal loss." | 1.72 | Pharmacological Rescue with SR8278, a Circadian Nuclear Receptor REV-ERBα Antagonist as a Therapy for Mood Disorders in Parkinson's Disease. ( Choe, HK; Choe, Y; Choi, JW; Choi, M; Jang, S; Kim, D; Kim, J; Kim, K; Moon, C; Park, I; Park, SH; Sun, W, 2022) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Kim, J | 1 |
Park, I | 1 |
Jang, S | 1 |
Choi, M | 1 |
Kim, D | 1 |
Sun, W | 1 |
Choe, Y | 1 |
Choi, JW | 1 |
Moon, C | 1 |
Park, SH | 1 |
Choe, HK | 1 |
Kim, K | 1 |
Carvalho, MM | 1 |
Campos, FL | 1 |
Coimbra, B | 1 |
Pêgo, JM | 1 |
Rodrigues, C | 1 |
Lima, R | 1 |
Rodrigues, AJ | 1 |
Sousa, N | 1 |
Salgado, AJ | 1 |
Petri, D | 1 |
de Souza Silva, MA | 1 |
Chao, OY | 1 |
Schnitzler, A | 1 |
Huston, JP | 1 |
Singh, S | 1 |
Mishra, A | 1 |
Srivastava, N | 1 |
Shukla, S | 1 |
4 other studies available for oxidopamine and Affective Disorders
Article | Year |
---|---|
Pharmacological Rescue with SR8278, a Circadian Nuclear Receptor REV-ERBα Antagonist as a Therapy for Mood Disorders in Parkinson's Disease.
Topics: Animals; Humans; Isoquinolines; Mice; Mood Disorders; Neurodegenerative Diseases; Nuclear Receptor S | 2022 |
Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits.
Topics: Adrenergic Agents; Animals; Antidepressive Agents; Antiparkinson Agents; Behavior, Animal; Bupropion | 2013 |
Serotonergic interaction between medial prefrontal cortex and mesotelencephalic DA system underlies cognitive and affective deficits in hemiparkinsonian rats.
Topics: Adrenergic Agents; Animals; Cognition Disorders; Disease Models, Animal; Excitatory Amino Acid Agoni | 2015 |
MK-801 (Dizocilpine) Regulates Multiple Steps of Adult Hippocampal Neurogenesis and Alters Psychological Symptoms via Wnt/β-Catenin Signaling in Parkinsonian Rats.
Topics: Adaptation, Ocular; Animals; beta Catenin; Cell Proliferation; Disease Models, Animal; Dizocilpine M | 2017 |